Join
Live feed
·
PRReleasevia Quantisnow
Sunesis Pharmaceuticals, Inc. logo

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
SNSS· Sunesis Pharmaceuticals, Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SNSS (Sunesis Pharmaceuticals, Inc.) and more on Quantisnow.